Page last updated: 2024-08-01 19:42:39
ancriviroc
Description
Ancriviroc: CCR5 receptor antagonist [MeSH]
Ancriviroc : no description available [CHeBI]
Cross-References
Synonyms (14)
| Synonym |
|---|
| CHEBI:177442 |
| [4-[4-[(e)-c-(4-bromophenyl)-n-ethoxycarbonimidoyl]piperidin-1-yl]-4-methylpiperidin-1-yl]-(2,4-dimethyl-1-oxidopyridin-1-ium-3-yl)methanone |
| 3-[(4-{4-[(1z)-(4-bromophenyl)(ethoxyimino)methyl]piperidin-1-yl}-4-methylpiperidin-1-yl)carbonyl]-2,4-dimethylpyridin-1-ium-1-olate |
| gtpl802 |
| [3h]sch-351125 |
| [3h]sch 351125 |
| gtpl804 |
| [3h]ancriviroc |
| ancriviroc |
| L000937 |
| chembl336672 , |
| schering c |
| SCHEMBL2939135 |
| Q27074462 |
Drug Classes (2)
| Class | Description |
|---|
| pyridinemonocarboxylic acid | A monocarboxylic acid in which the carboxy group is attached to a pyridine (or substituted pyridine) ring. |
| aromatic carboxylic acid | Any carboxylic acid in which the carboxy group is directly bonded to an aromatic ring. |
Protein Targets (1)
Inhibition Measurements
Bioassays (10)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1346815 | Human CCR5 (Chemokine receptors) | 2006 | The Journal of biological chemistry, May-05, Volume: 281, Issue:18
ISSN: 0021-9258 | Structural and molecular interactions of CCR5 inhibitors with CCR5. |
| AID1346815 | Human CCR5 (Chemokine receptors) | 2001 | Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
ISSN: 0022-2623 | Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. |
| AID1346815 | Human CCR5 (Chemokine receptors) | 2005 | Antimicrobial agents and chemotherapy, Dec, Volume: 49, Issue:12
ISSN: 0066-4804 | Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. |
| AID589850 | Volume of distribution at steady state in rat at 10 umol/kg, iv | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
ISSN: 1464-3405 | Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication. |
| AID589848 | Clearance in rat at 10 umol/kg, iv | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
ISSN: 1464-3405 | Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication. |
| AID589846 | AUC (0 to infinity) in rat | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
ISSN: 1464-3405 | Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication. |
| AID589854 | Oral bioavailability in rat at 100 umol/kg | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
ISSN: 1464-3405 | Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication. |
| AID589844 | Cmax in rat | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
ISSN: 1464-3405 | Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication. |
| AID589842 | Antiviral activity against Human immunodeficiency virus 1 BAL infected in human PBMC assessed as inhibition of viral replication by p24 antigen specific ELISA | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
ISSN: 1464-3405 | Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication. |
| AID589852 | Half life in rat at 10 umol/kg, iv | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
ISSN: 1464-3405 | Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication. |
| AID589841 | Displacement of [128I]-RANTES from CCR5 expressed in HEK293F cells | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
ISSN: 1464-3405 | Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication. |
| AID589843 | Cytotoxicity against human PBMC | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
ISSN: 1464-3405 | Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication. |
Research
Studies (30)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 27 (90.00) | 29.6817 |
| 2010's | 3 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 2 (6.67%) | 5.53% |
| Reviews | 2 (6.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 26 (86.67%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| niacin | | pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3 | antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| picolinic acid | | pyridinemonocarboxylic acid | human metabolite;
MALDI matrix material | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methaniazide | | aromatic carboxylic acid;
pyridinemonocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isonicotinic acid | | pyridinemonocarboxylic acid | algal metabolite;
human metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| picloram | | aminopyridine;
chloropyridine;
organochlorine pesticide;
pyridinemonocarboxylic acid | herbicide;
synthetic auxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clonixin | | aminopyridine;
organochlorine compound;
pyridinemonocarboxylic acid | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
lipoxygenase inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flunixin | | aminopyridine;
organofluorine compound;
pyridinemonocarboxylic acid | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| imazapyr, (+-)-isomer | | imidazolines;
imidazolone;
pyridinemonocarboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| egyt 475 | | aromatic carboxylic acid;
pyridinemonocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| raptors | | ether;
imidazolines;
imidazolone;
pyridinemonocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ac 263,222 | | imidazolines;
imidazolone;
methylpyridines;
pyridinemonocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [4-[oxo(thiophen-2-yl)methyl]-1-piperazinyl]-(3-pyridinyl)methanone | | aromatic carboxylic acid;
pyridinemonocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [3-(2-furanyl)-5-(thiophen-2-ylmethylamino)-1,2,4-triazol-1-yl]-(3-pyridinyl)methanone | | aromatic carboxylic acid;
pyridinemonocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N'-[(2-nitrophenyl)-oxomethyl]-2-pyridinecarbohydrazide | | aromatic carboxylic acid;
pyridinemonocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N'-[(3-nitrophenyl)-oxomethyl]-2-pyridinecarbohydrazide | | aromatic carboxylic acid;
pyridinemonocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [5-(4-bromophenyl)-3-(2-hydroxyphenyl)-3,4-dihydropyrazol-2-yl]-pyridin-4-ylmethanone | | aromatic carboxylic acid;
pyridinemonocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (5-bromo-3-pyridinyl)-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone | | aromatic carboxylic acid;
pyridinemonocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| salinazid | | aromatic carboxylic acid;
pyridinemonocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fusaric acid | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| niflumic acid | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxolinic acid | | aromatic carboxylic acid;
organic heterotricyclic compound;
oxacycle;
quinolinemonocarboxylic acid;
quinolone antibiotic | antibacterial drug;
antifungal agent;
antiinfective agent;
antimicrobial agent;
enzyme inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thurfyl nicotinate | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methyl nicotinate | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| piperonylic acid | | aromatic carboxylic acid;
benzodioxoles;
monocarboxylic acid | antifungal agent;
EC 1.14.14.91 ( trans-cinnamate 4-monooxygenase) inhibitor;
plant metabolite;
vulnerary | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| citrazinic acid | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nicoboxil | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxiniacic acid | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-hydroxynicotinic acid | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| imazethapyr | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-hydroxynicotinic acid | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethylnicotinate | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nicametate | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-Chloronicotinic acid | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sofosbuvir | | aminopyrimidine;
aromatic carboxylic acid;
nucleobase analogue;
pyrimidone | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-chloronicotinic acid | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thiazopyr | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-phenazinecarboxylic acid | | aromatic carboxylic acid;
monocarboxylic acid;
phenazines | antifungal agent;
antimicrobial agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methylthiazole-5-carboxylic acid | | aromatic carboxylic acid;
thiazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-methyl-2-oxo-5-[oxo-(1-phenylethylamino)methyl]-1H-pyridine-3-carboxylic acid ethyl ester | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-pyridinecarboxylic acid [2-(2,3-dichloroanilino)-2-oxoethyl] ester | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4,5-dichloro-3-isothiazolecarboxylic acid [1-(2-furanylmethylamino)-1-oxopropan-2-yl] ester | | aromatic carboxylic acid;
thiazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-cyano-2-methyl-6-sulfanylidene-1H-pyridine-3-carboxylic acid ethyl ester | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,4-Dimethyl-1,3-thiazole-5-carboxylic acid | | aromatic carboxylic acid;
thiazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-amino-3-phenyl-2-sulfanylidene-5-thiazolecarboxylic acid methyl ester | | aromatic carboxylic acid;
thiazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-phenylethylthio)-3-pyridinecarboxylic acid | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(2-oxopropylthio)-3-pyridinecarboxylic acid | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[(5-ethyl-2-thiophenyl)-oxomethyl]amino]-4-methyl-5-thiazolecarboxylic acid ethyl ester | | aromatic carboxylic acid;
thiazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-ethoxy-3-pyridinecarboxylic acid [2-[1-(2-furanylmethyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl] ester | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[2-[[4-hydroxy-6-oxo-5-(phenylmethyl)-1H-pyrimidin-2-yl]thio]-1-oxoethyl]amino]-4-methyl-5-thiazolecarboxylic acid ethyl ester | | aromatic carboxylic acid;
thiazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5,6-dichloro-3-pyridinecarboxylic acid [2-(2-furanylmethylamino)-2-oxoethyl] ester | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-pyridinecarboxylic acid [2-[1-(2-furanylmethyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl] ester | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-methyl-2-(2-phenylethylamino)-4-thiazolecarboxylic acid ethyl ester | | aromatic carboxylic acid;
thiazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-oxo-1H-pyridine-3-carboxylic acid [2-(2,5-dimethyl-1-propyl-3-pyrrolyl)-2-oxoethyl] ester | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,6-dimethyl-4-(3-thienyl)pyridine-3,5-dicarboxylic acid | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-cyano-2-(methoxymethyl)-6-sulfanylidene-1H-pyridine-3-carboxylic acid methyl ester | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(propylthio)nicotinic acid | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-Thienyl)-1,3-thiazole-4-carboxylic acid | | aromatic carboxylic acid;
thiazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glucitol hexanicotinate | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4,5-dichloro-3-isothiazolecarboxylic acid [1-oxo-1-(thiophen-2-ylmethylamino)butan-2-yl] ester | | aromatic carboxylic acid;
thiazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-pyridinecarboxylic acid [2-(5-chloro-2-thiophenyl)-2-oxoethyl] ester | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]thio]-3-pyridinecarboxylic acid [2-[(2-methoxyphenyl)methylamino]-2-oxoethyl] ester | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(5-chloro-2-thiophenyl)-oxomethyl]imino-3,4-dimethyl-5-thiazolecarboxylic acid ethyl ester | | aromatic carboxylic acid;
thiazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(5-formyl-2-methoxyphenyl)methylthio]-3-pyridinecarboxylic acid | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-pyridinecarboxylic acid [2-[2-(difluoromethoxy)anilino]-2-oxoethyl] ester | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-fluoroanilino)-3-pyridinecarboxylic acid [2-[(1,1-dioxo-3-thiolanyl)-methylamino]-2-oxoethyl] ester | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ciclonicate | | aromatic carboxylic acid;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
Development of a novel high-throughput surrogate assay to measure HIV envelope/CCR5/CD4-mediated viral/cell fusion using BacMam baculovirus technology.Journal of biomolecular screening, , Volume: 8, Issue:4, 2003
Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist.Bioorganic & medicinal chemistry letters, , Feb-24, Volume: 13, Issue:4, 2003
Update from Seattle: the 9th Annual Retrovirus Conference.The AIDS reader, , Volume: 12, Issue:4, 2002
Researchers explore new anti-HIV agents.JAMA, , Apr-03, Volume: 287, Issue:13, 2002
An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry.Virology, , Sep-01, Volume: 352, Issue:2, 2006
HIV entry and fusion inhibitors.Expert opinion on emerging drugs, , Volume: 9, Issue:1, 2004
Update from Seattle: the 9th Annual Retrovirus Conference.The AIDS reader, , Volume: 12, Issue:4, 2002
Drugs in development.AIDS patient care and STDs, , Volume: 16, Issue:5, 2002
9th National Retrovirus Conference: new treatments, new choices.AIDS patient care and STDs, , Volume: 16, Issue:5, 2002
Sch-351125 and Sch-350634. Schering-Plough.Current opinion in investigational drugs (London, England : 2000), , Volume: 3, Issue:3, 2002
Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro.Antimicrobial agents and chemotherapy, , Volume: 46, Issue:5, 2002
Researchers explore new anti-HIV agents.JAMA, , Apr-03, Volume: 287, Issue:13, 2002
An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry.Virology, , Sep-01, Volume: 352, Issue:2, 2006
HIV entry and fusion inhibitors.Expert opinion on emerging drugs, , Volume: 9, Issue:1, 2004
Update from Seattle: the 9th Annual Retrovirus Conference.The AIDS reader, , Volume: 12, Issue:4, 2002
Drugs in development.AIDS patient care and STDs, , Volume: 16, Issue:5, 2002
9th National Retrovirus Conference: new treatments, new choices.AIDS patient care and STDs, , Volume: 16, Issue:5, 2002
Sch-351125 and Sch-350634. Schering-Plough.Current opinion in investigational drugs (London, England : 2000), , Volume: 3, Issue:3, 2002
Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro.Antimicrobial agents and chemotherapy, , Volume: 46, Issue:5, 2002
Researchers explore new anti-HIV agents.JAMA, , Apr-03, Volume: 287, Issue:13, 2002
Long-term Use (1)
Bioavailability (5)
| Article | Year |
|---|
Oximino-piperidino-piperidine-based CCR5 antagonists. Part 2: synthesis, SAR and biological evaluation of symmetrical heteroaryl carboxamides.
Bioorganic & medicinal chemistry letters, , Feb-24, Volume: 13, Issue:4 | 2003 |
Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist.
Bioorganic & medicinal chemistry letters, , Feb-24, Volume: 13, Issue:4 | 2003 |
Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity.
Journal of medicinal chemistry, , Jul-04, Volume: 45, Issue:14 | 2002 |
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.
Proceedings of the National Academy of Sciences of the United States of America, , Oct-23, Volume: 98, Issue:22 | 2001 |
Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection.
Journal of medicinal chemistry, , Oct-11, Volume: 44, Issue:21 | 2001 |